Cypress Asset Management Inc. TX lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 117,762 shares of the company’s stock after selling 5,428 shares during the period. Johnson & Johnson makes up approximately 2.8% of Cypress Asset Management Inc. TX’s investment portfolio, making the stock its 3rd largest position. Cypress Asset Management Inc. TX’s holdings in Johnson & Johnson were worth $14,285,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in JNJ. Americafirst Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $101,000. Capital Asset Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $202,000. D. Scott Neal Inc. increased its stake in shares of Johnson & Johnson by 4.1% in the second quarter. D. Scott Neal Inc. now owns 1,840 shares of the company’s stock valued at $223,000 after buying an additional 72 shares in the last quarter. Terra Nova Asset Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $243,000. Finally, Daiwa SB Investments Ltd. increased its stake in shares of Johnson & Johnson by 8.4% in the second quarter. Daiwa SB Investments Ltd. now owns 2,970 shares of the company’s stock valued at $354,000 after buying an additional 230 shares in the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) traded down 0.59% during trading on Friday, hitting $117.56. The company had a trading volume of 5,640,519 shares. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company has a market capitalization of $321.63 billion, a price-to-earnings ratio of 21.91 and a beta of 0.62. The stock has a 50-day moving average of $118.72 and a 200 day moving average of $117.37.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. Equities analysts forecast that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
JNJ has been the subject of several research analyst reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research note on Monday, August 22nd. Barclays PLC reaffirmed an “overweight” rating and issued a $125.00 target price (up from $120.00) on shares of Johnson & Johnson in a research report on Sunday, July 10th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research report on Friday, August 5th. BTIG Research reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. Finally, Jefferies Group upped their target price on Johnson & Johnson from $109.00 to $113.00 and gave the stock a “hold” rating in a research report on Thursday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and an average target price of $120.20.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.